Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 11/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714677 | 0.97 | SCN9A (0.36) | SCN9AADAM17CACNA1GCACNA1HCACNA1I | |
| SCHEMBL30714699 | 0.95 | ADAM17 (0.39) | SCN9AADAM17MMP13 | |
| SCHEMBL30714603 | 0.91 | ADAM17 (0.34) | ADAM17CACNA1GCACNA1HCACNA1IMMP13 | |
| SCHEMBL30714631 | 0.87 | OPRL1 (0.33) | ADAM17CACNA1GCACNA1HCACNA1IMMP13 | |
| SCHEMBL30714628 | 0.85 | PARP15 (0.40) | ADAM17MMP13 | |
| SCHEMBL30714749 | 0.85 | OPRL1 (0.35) | OPRL1GRM2 | |
| SCHEMBL30714582 | 0.85 | CNR2 (0.37) | OPRL1 | |
| SCHEMBL30714600 | 0.84 | TYK2 (0.38) | CACNA1GCACNA1HCACNA1IOPRL1GRM2 | |
| SCHEMBL26696044 | 0.84 | CYP4F2 (0.34) | ADAM17CACNA1GCACNA1HCACNA1IMMP13 | |
| SCHEMBL30714557 | 0.83 | NPC1 (0.37) | OPRL1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SCN9A 518/4885ADAM17 3090/4885CACNA1G 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.